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Mesenchymal stem/stromal cells (MSCs) and MSC-like multipotent stem/progenitor cells have been widely investigated for
regenerativemedicine anddeemedpromising in clinical applications. In order to further improveMSC-based stemcell therapeutics,
it is important to understand the cellular kinetics and functional roles ofMSCs in the dynamic regenerative processes. However, due
to the heterogeneous nature of typical MSC cultures, their native identity and anatomical localization in the body have remained
unclear, making it difficult to decipher the existence of distinct cell subsets within the MSC entity. Recent studies have shown that
several blood-vessel-derived precursor cell populations, purified by flow cytometry frommultiple human organs, give rise to bona
fide MSCs, suggesting that the vasculature serves as a systemic reservoir of MSC-like stem/progenitor cells. Using individually
purified MSC-like precursor cell subsets, we and other researchers have been able to investigate the differential phenotypes and
regenerative capacities of these contributing cellular constituents in the MSC pool. In this review, we will discuss the identification
and characterization of perivascular MSC precursors, including pericytes and adventitial cells, and focus on their cellular kinetics:
cell adhesion, migration, engraftment, homing, and intercellular cross-talk during tissue repair and regeneration.
1. Introduction
The availability of mesenchymal stem/stromal cells (MSCs)
and MSC-like multipotent stem/progenitor cells marked a
major milestone in stem cell therapies [1, 2]. For more
than a decade, MSC has been a highly promising stem
cell source and extensively investigated for its therapeutic
potentials [3, 4]. Unlike embryonic stem cells (ESCs) or
induced pluripotent stem cells (iPSCs), MSCs are inherently
more relevant to clinical applications due to the lack of ethical
and safety issues, despite lower developmental versatility [5].
MSCs and similar mesodermal stem/progenitor cells have
been shown to repair and/or regenerate a wide variety of
damaged/defective organs, including bone, cartilage, muscle,
heart, and skin [6–10]. MSCs have also been reported to
support hematopoiesis and suppress immune reaction after
cell/organ transplantation [11–14].
Nevertheless, owing to the nature of MSC isolation by
plastic adherence in tissue culture, the native identity and
anatomical localization of MSCs have remained unclear for
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years [15]. Recently, several studies have indicated that MSCs
represent a heterogeneous entity in culture, and a number
of multipotent precursor cells potentially contributing to the
MSC pool have been identified in vivo [16, 17]. Increasing
evidence further suggests thatMSCs and some tissue-specific
progenitor cells are anatomically and functionally associated
with vascular/perivascular niches in various tissues [18–
21]. Following the hypothesis that blood vessels through-
out the body serve as a systemic reservoir of multipotent
stem/progenitor cells, we and other researchers have iden-
tified, purified, and characterized distinct populations of
MSC-like multilineage precursors from the vasculature of
multiple human organs [17, 22]. These human blood vessel-
derived precursor cell subsets, including pericytes (PCs)
[23], adventitial cells (ACs) [24], and myogenic endothelial
cells (MECs) [25], can be isolated via fluorescence-activated
cell sorting (FACS) based on their unique expression of
cell surface antigens. Purified PCs, ACs, and MECs not
only exhibit typical mesodermal multipotency in culture but
also demonstrate robust regenerative capacities in animal
disease models. Consequently these precursor cell subsets,
particularly PCs andACs that can be universally derived from
definitive structures of blood vessel walls, represent active
contributors to the MSC entity [17].
In this review, we will discuss the identification and
characterization of perivascular MSC precursors (i.e., PCs
and ACs) from multiple organs and focus on their cellular
kinetics during regenerative events, including cell adhesion,
migration, engraftment, homing, and intercellular cross-talk.
2. Native Distribution of MSCs and MSC-Like
Multipotent Stem/Progenitor Cells
MSCs andMSC-like stem/progenitor cells have been found in
nearly all organs in the humanbody.Despite slight differences
in phenotypes and cellular functions, MSCs and MSC-like
cells from various ontogenies share basic features in general,
including selective plastic adherence, expression of typical
MSC surface markers, and mesenchymal multipotency such
as osteogenesis, chondrogenesis, and adipogenesis. Some of
the most commonMSCs andMSC-like multilineage cells are
briefly introduced here.
2.1. Bone Marrow-Derived MSCs (BM-MSCs). Bone marrow
(BM) harbors multiple types of stem/progenitor cells, includ-
ing hematopoietic stem cells (HSCs), endothelial progenitor
cells (EPCs), and BM-MSCs [26, 27]. As a standard MSC
population, BM-MSCs are defined as nonhematopoietic,
plastic adherent progenitor cells that self-renew, differentiate
into typical mesodermal cell lineages including osteogenic,
chondrogenic, and adipogenic lineages, and express CD73,
CD90, and CD105 but are negative for CD11b, CD14, CD19,
CD34, CD45, CD79𝛼, and HLA-DR1 [28]. Estimated by the
colony forming unit fibroblasts assay (CFU-F) in vitro, BM-
MSCs typically exist at a very low frequency within the
BM mononucleated cell population (0.01%–0.1% of total BM
cells) but can be efficiently expanded in culture, making them
one of the most investigated autologous stem/progenitor
cell populations. Interestingly, multipotent BM-MSC clones
retain approximately twofold higher CD146 expression level
than unipotent clones [29].
2.2. Adipose-Derived Stem/Stromal Cells (ASCs). The stro-
mal vascular fraction (SVF) of adipose can be isolated
via enzymatic digestion of intact fat tissue or lipoaspirate,
followed by the depletion of mature adipocytes through
centrifugation.TheSVF embodies a broad andheterogeneous
cellular compartment, including vascular cells (endothelial
and perivascular populations), hematopoietic cells (resident
and circulating cells), and stromal fibroblasts. In 1976, human
adipogenic progenitors (aka preadipocytes) were success-
fully isolated by two independent groups from the adipose
SVF by selective adherence to culture plastics [30, 31]. The
adherent fraction of the adipose SVF was later identified
as a source of mesenchymogenic progenitors [32], termed
adipose-derived stem/stromal cells (ASC) [33]. ASCs are
defined in vitro using the same criteria as bona fide BM-
MSCs [34], including their selective plastic adherence, mes-
enchymal differentiation capacities and immunophenotypes
[32], although ASCs only resemble BM-MSCs at subsequent
passages in culture [35]. Unlike BM-MSCs, early-passage
ASCs temporarily retain expression of mucosialin (CD34)
[35], a well-established marker for stem/progenitor cells in
both hematopoietic [36] and endothelial [37] cell lineages.On
another note, the temporary retention of CD34 expression
in primary ASCs led to confusion regarding their origin
in situ. This misperception was accentuated in light of the
recent characterization of CD34-negative PCs as a source
of MSCs in a variety of mesodermal tissues, including fat
[23]. While the adipogenic activity is mainly exhibited by the
prevalent CD34+/CD31− subset of the adipose SVF [38], the
CD34-negative fraction can also generate ASCs in vitro [24,
39, 40]. Immunohistochemical studies have confined these
mesenchymogenic subpopulations to the adipose microvas-
culature where they coexist, respectively, in the media and
adventitia in an annular fashion [24, 39, 41, 42]. Both PCs
and an outer supra-adventitial layer of CD34-positive cells
(adventitial cells/supra-adventitial stromal cells, ACs) possess
high adipogenic potential in vitro [39, 43] andmay contribute
together to replenish the pool of adipocytes essential to
sustain the high fat turnover in vivo [44].
2.3. Umbilical Cord-Derived Mesenchymal Stem/Stromal Cells
(UC-MSCs). Stem/progenitor cells isolated from disposable
perinatal tissues, including amnion/amniotic fluid, umbilical
cord blood, placental tissue, umbilical cord blood vessels, and
the Wharton’s jelly, have been deemed promising for clinical
applications because of the minimal safety and ethical con-
cerns [45, 46]. MSCs and MSC-like cells have been isolated
from different compartments of the umbilical cord, including
umbilical vein subendothelial zone, umbilical cord blood,
and specifically,Wharton’s jelly [45, 47].Wharton’s jelly is the
parenchyma within the umbilical cord, a mucoid connective
tissue surrounding umbilical cord arteries and vein [45]. The
Wharton’s jelly can be further divided into three anatomical
regions where MSCs can be derived from the perivascular
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zone, the intervascular zone, and the subamnion [47]. Similar
to BM-MSCs, MSCs derived from Wharton’s jelly exhibit
plastic adherence, mesenchymal multipotency, and expres-
sion of CD10, CD13, CD29, CD44, CD73, CD90, CD105, and
HLA-class I but are negative for CD11b, CD14, CD19, CD31,
CD34, CD45, CD56, CD79, and HLA class II [45–47].
3. Blood Vessels as a Source of
MSC Precursors
The similarities between MSCs derived from many different
tissues aroused the idea that a common reservoir of MSCs
may exist in the body. The blood vessel, which typically
consists of three structural layers: tunica intima, tunicamedia,
and tunica adventitia [48], is distributed throughout nearly all
human organs and therefore represents a favorable candidate.
Early evidence supporting the hypothesis that the vascular
wall serves as a systemic source of stem cells came from a
study of the emerging hematopoietic system in the embryo
and fetus, where hematopoietic cells emerged in close vicinity
to vascular endothelial cells (ECs) in both intra- and extraem-
bryonic blood-forming tissues [22]. Recently, several studies
have indicated the possibility that blood vessels in different
organs contain multilineage precursors that possess MSC-
like features and contribute to tissue repair/regeneration [49,
50]. New evidence further pointed out that tissue-specific
multipotent stem/progenitor cells, including osteogenic, neu-
ral, odontoblastic, and adipogenic progenitors, may originate
from and/or associate with vascular/perivascular niches in
vivo [18–21].
Microvascular pericytes (PCs), a set of perivascularmural
cells surrounding the intima of microvessels and capillaries,
are traditionally regarded as a structural component of
blood vessels, regulating vascular contractility, stability, and
integrity [51, 52]. Intimate interactions between PCs and ECs
tightly regulate vascular growth, maturation, and remodeling
[51, 53–55]. Recently, PCs have been implicated in a number
of pathological conditions, making them potential targets
for therapeutic interventions [55, 56]. On the other hand,
the tunica adventitia, the outermost layer of large blood
vessels, has long been considered as a structural bystander,
consisting of loosely structured collagen-rich extracellular
matrix (ECM), which embeds stromal cells/fibroblasts, the
vasa vasorum, and perivascular nerves [57]. The importance
of the tunica adventitia was recently reevaluated due to
a number of studies reporting its active role in vascular
remodeling, immune response mediation, cell trafficking,
and atherosclerosis [57–59]. In a vascular remodeling setting
following an injury, it has been shown that adventitial cells
(ACs) start a process of proliferation, migration into the
tunicae media and intima, and differentiation into smooth
muscle cells [60–62]. Recently, we and several other groups
reported new strategies for the identification and purification
of the elusive PCs and ACs [23, 24, 39, 63–65]. Using
immunohistochemistry and flow cytometry, we identified
human PCs and ACs in situ and purified these cells to
homogeneity based on their unique expressions of cell surface
antigens. Details of the isolation and characterization of PCs
and ACs will be described in the following sections.
Unlike the tunicae media and adventitia, the subendothe-
lial zone of tunica intima has previously been suggested
as one of the sources of EPCs [66, 67]. Apart from PCs
and ACs, some of us have also reported a rare but distinct
subset of blood-vessel-derived stem cells, that is, myogenic
endothelial cells (MECs), residing within the intima of
microvasculature in human skeletal muscle [25]. MECs,
presumably the human counterpart ofmurinemuscle derived
stem cells (MDSCs), not only express the myogenic cell
marker, CD56, but also display endothelial cell markers,
CD34 and CD144. Following purification by FACS, MECs
(CD34+/CD56+/CD144+/CD45−) can be clonally expanded
and exhibited osteo-, chondro-, adipo-, and myogenic dif-
ferentiation capacities in vitro [25]. Furthermore, MECs
exhibited superior cardiac repair capacity in ischemic hearts
and myogenic regeneration in injured skeletal muscle than
conventional CD56+ myoblasts and ECs [25, 68, 69]. Nev-
ertheless, despite their MSC-like features and tissue repara-
tive/regenerative capability, whetherMECs contribute signif-
icantly to the MSC entity remains to be clarified due to their
restricted presence in skeletal muscle.
4. Identification and Purification of
Perivascular MSC Precursors
4.1. Placenta. While placenta and umbilical cord are often
discarded at birth, these extraembryonic tissues contain
large numbers of stem/progenitor cells, making them attrac-
tive sources of donor cells for regenerative medicine.
We and others have isolated multipotent PCs (CD146+/
CD34−/CD45−/CD56−) from these tissues and utilized them
towardmultiple tissue repair/regeneration, including skeletal
muscle [70], lung [71], dermal [72], and nervous tissues [73].
Placenta is a highly vascularized extraembryonic tissue,
which serves as fetomaternal interface to sustain proper
oxygen transportation, waste disposal, and nutrient delivery.
The placental vasculature has been thoroughly characterized
throughout fetal development previously and consists of all
sizes/types of blood vessels and both pericytes/perivascular
cells and ECs at all stages [74, 75]. Placenta PCs are critical to
maintain blood vessel homeostasis and promote angiogenesis
[76, 77]. PC abnormity in placenta capillaries leads to defects
in sinusoidal integrity, a phenotype often observed during
pregnancy complications due to diabetes, postmaturity, or
preeclampsia [78]. In addition to their supportive role in the
fetal vasculature, placental PCs have also been identified as
a source of MSCs [23, 70, 79]. Our previous studies have
discriminated mesenchymogenic placental PCs based on the
expression of the cell adhesion molecule CD146 and lack of
ECmarkers: CD34, CD144, and vWF [23, 70]. Similarly, Cas-
trechini et al. described a perivascular population residing in
human fetal and term placenta, which coexpressed MSC/PC
markers (Stro-1, 3G5, CD105, CD106, CD146, CD49a, 𝛼-
SMA) but not hematovascular markers (CD117, CD34, vWF)
and were competent for trilineage mesenchymal differentia-
tion [79]. In our hands, human fetal and term chorionic villi
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Figure 1: Flow cytometry analysis of mesenchymal stem cell marker expression in freshly isolated fetal and term placental pericytes. (a)
Representative flow cytometry analysis of human placenta that was mechanically dissociated and enzymatically digested and subsequently
stained for CD45, CD56, CD34, and CD146 along with CD44, CD73, CD90, or CD105. Matching isotype controls were shown in the left
column. (b) Human fetal placenta (𝑁 = 3, average 20 weeks of gestation) and term placenta (𝑁 = 2, average 39 weeks of gestation) were used
to isolate subsets of pericytes using surface expression of CD146+/CD34−/CD45−/CD56− (CD146+/−/−/−) and colabeled with one of the
mesenchymal stem cell markers (CD146+/CD44+, CD146+/CD73+, CD146+/CD90+, CD146+/CD105+) as shown in (a). Values are mean ±
standard error.
of placentas included 8.5 ± 3.66% (𝑁 = 3, 19 to 21 weeks of
gestation) and 2.1 ± 0.43% (𝑁 = 2, 39 weeks of gestation)
of PCs (CD146+/CD34−/CD45−/CD56−), respectively (Fig-
ure 1).
The native expression of CD146 by mesenchymogenic
PCs in many tissues including bone marrow, fetal and term
placentas has been reported [23, 70]. Using FACS, we puri-
fied PCs from mechanically and enzymatically dissociated
placental chorionic villi [23, 70]. Freshly isolated placenta
PCs natively expressed MSC markers (CD44, CD73, CD90,
and CD105) at varying levels (30 to 87% of fetal and 20
to 48% of term placental CD146+/CD34−/CD45−/CD56−
PCs) (Figure 1). We have previously demonstrated that when
placed onto ECM-coated plates, dissected fetal placental villi
release a population of vascular cells, which possess high
migratory activity and robust capacity to regenerate skeletal
muscle fibers in dystrophic mice [70]. The cells migrating
out of placental villi included predominantly CD146+ cells
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which coexpressedPC (NG2 andPDGFR𝛽) andMSC (CD44,
CD73, CD90, andCD105) surface antigens andwere deprived
of EC antigens (CD31, CD34, CD144, and vWF) [70]. Maier
et al. employed a similar approach to isolate PCs from the
cellular outgrowth of human term placenta explants [80].
Consistently with fetal placenta, term placenta PCs expressed
high levels of PC/MSC markers (CD146, PDGFR𝛽, NG2,
CD90, and calponin), including 65 transcripts that are highly
expressed in undifferentiated MSCs, and lacked endothe-
lial/hematopoietic cell marker expression (CD31, CD34, and
CD45) [80].
4.2. Umbilical Cord. Human umbilical cord (HUC) has been
known as an abundant source of ECs as well as MSCs derived
from the Wharton’s jelly. Recently some of us demonstrated
that human full-term UCs and, at a higher frequency, fetal
(preterm) UCs contain perivascular cells that exhibit fea-
tures of MSCs. These perivascular smooth muscle-like cells
present in the HUC co-expressed CD146 and alpha-smooth
muscle actin (𝛼SMA) but did not express the established
EC markers: CD144, CD34, CD31, and Ulex europaeus
agglutinin (UEA-1) receptor. Using FACS, Montemurro et
al. isolated a population of PCs (CD146+/NG2+/PDGFR𝛽+)
from umbilical cords of preterm newborns [71]. These HUC-
derived perivascular cells (HUCPCs) can be maintained
in long-term culture, exhibiting classical spindle-shape PC
morphology. When characterized by flow cytometry during
subsequent passages, they maintained the expression of
CD44, CD90, CD73, CD105, HLA class I, CD146, NG2,
𝛼SMA, and PDGFR𝛽 as well as retained their multipo-
tency to differentiate towards different cell types, including
osteogenic, adipogenic, and myogenic cell lineages [71].
4.3. Skeletal Muscle. Skeletal muscle has been shown to
harbor several adult stem/progenitor cell populations in
mammals including humans, in addition to the typical
muscle stem cells, that is, satellite cells [81–83]. Many studies
have demonstrated that muscle derived stem/progenitor cells
are capable of differentiating into a variety of cell lineages in
vitro and in vivo, including blood cells and fat [25, 81, 84–
86]. Using similar immunohistochemical and flow cytometry
strategies, we first identified microvascular PCs in situwithin
human skeletal muscle and subsequently purified them from
mechanically and enzymatically dissociated muscle biopsies
via FACS [23]. Similar to PCs sorted from other tissues, mus-
cle PCs (CD146+/CD34−/CD45−/CD56−) expressed typical
PC markers: CD146, NG2, PDGFR-𝛽, alkaline phosphatase
(ALP), and 𝛼-smooth muscle actin (𝛼-SMA), with the
absence of EC markers: CD31, CD34, CD144, and vWF as
well as the hematopoietic cell marker CD45 and myogenic
cell marker CD56. Muscle PCs can be efficiently expanded
in culture, at the clonal level, while maintaining robust meso-
dermal developmental potentials. Freshly isolated and long-
term cultured muscle PCs both displayed robust myogenic
capacity in vitro and in vivo. Moreover, muscle PCs natively
and in culture expressed classic MSC markers: CD44, CD73,
CD90, and CD105, indicating their developmental status as
MSC ancestors [23].
4.4. Adipose. Vasculogenic CD34+/CD31− cell populations
have been described in the adventitial vasa vasorum of
large blood vessels such as the vena saphena [65] and the
thoracic aorta [67], but microvascular CD34+ ACs seem
to be a specific feature of the adipose and subcutaneous
tissue [87]. Apart from CD34 expression and their adjacent
anatomical localization within the blood vessel wall, ACs can
be discriminated from adipose PCs due to the lack of native
expression of PC markers (𝛼SMA, CD146, NG2, PDGFR𝛽)
[24, 39, 42]. The high prevalence (∼50%) of CD34+/CD146−
progenitor cells in the nonhematopoietic adipose SVF [39,
88, 89] and their limited clonogenicity and heterogeneous
proliferative capacity [24] do not preclude the possibility
that distinct CD34+ stem/progenitor cells exist within adult
adipose tissue. Using a peroxisome proliferator-activated
receptor gamma (PPAR𝛾) reporter mouse model, Tang et
al. demonstrated that adipogenic progenitors emerge from
CD34+ cells which later adopt a perivascular niche and
express PC markers (𝛼SMA, NG2, PDGFR𝛽) [21]. Similarly,
human adiposeCD34+/CD146−ACs can acquire PCmarkers
(𝛼SMA, CD146, NG2, PDGFR𝛽) in vitro, following treatment
with angiotensin II or angiopoietin-2 [24].
While developmentally mesenchymogenic PCs may arise
from transient CD34+ cell population(s), the persistence of
such CD34+ precursors in the adult and their ontological
relationship to the bulk of CD34+ ACs in human fat will
require further investigation. Indeed, rare CD34+mesenchy-
mogenic cells have been reported in fetal [24, 90, 91] and
adult [92, 93] bone marrow, as well as in fetal muscle
and fetal lung [24]. A multipotent CD34+ cell population
residing in the wall of dorsal aorta, the mesoangioblast,
has been proposed to be an ancestor of adult mesenchy-
mogenic PCs in the mouse [49, 81]. Some groups have
reported the direct derivation of CD34+ primitive MSCs
from human embryonic stem cells (hESC) [94, 95], while
Vodyanik et al. described the emergence of a multipotent
MSC precursor, the mesenchymoangioblast, from hESC-
derived CD34+ cells in a stepwise differentiation system
[96]. Furthermore, Dar et al. recently reported successful
derivation of CD105+/CD90+/CD73+/CD31− multipotent
mesodermal precursors from embryoid bodies of either
human ESCs or iPSCs that exhibit clonogenicity, mesenchy-
mal differentiation potentials, and bona fide pericyte features,
including angiogenic/vasculogenic capacity and expression
of CD146, NG2, and PDGFR𝛽 but not 𝛼SMA, CD56, CD34,
or EC markers [97]. These hPSC-derived PCs significantly
facilitated vascular and muscle regeneration when trans-
planted into the ischemic limb of immunodeficient mice,
with the presence of hPSC-PCs in both recovered vasculature
and myofibers, indicating robust vasculogenic and myogenic
capacities in vivo similar to their adult counterparts [97]. Yet,
the reciprocity of all these fetal populations to all or part of
adult MSC precursors remains to be clarified.
A rare CD34+/CD146+/CD31−/CD45− population of
adipose PCs has also been characterized in the SVF [39,
98–103] and may represent a developmental intermediate
between PCs and some or all ACs [102]. This elusive
CD34+ PC population is not easily detected within the
vascular wall by immunohistochemistry [24, 42] and requires
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stringent rare-event strategies for its detection and isolation
by flow cytometry [100, 103]. Traktuev et al. suggested
the existence of CD34+ cells exhibiting a native pericytic
phenotype [98]. They demonstrated that primary cultures
of AC-like CD34+CD144−CD45− SVF cells can express PC
markers (NG2, PDGFR𝛼, PDGFR𝛽) without requirement
of blood vessel remodeling growth factors in contrast to
CD34+CD146− cells [24]. Though these disparities may be
related to culture conditions, SVF isolation techniques, and
cell sorting strategies, the intricacy and anatomical proximity
of these distinct subpopulations highlight the necessity to use
multidimensional strategies for their isolation via exclusion
of hematopoietic (CD45) and endothelial (CD31, CD144)
lineages and combinatory positive selection of pericytic (i.e.,
CD146, NG2, PDGFR𝛽), adventitial (CD34), orMSC (CD44,
CD73, CD90, CD105) cell subsets. A number of studies have
employed preliminary sorting strategies relying on single
markers, such as CD146 [104, 105] or CD34 [40, 106, 107],
which may be inadequate in regard to the overlapping phe-
notypes of the vascular/perivascular cell subsets populating
the adipose tissue.
Recently, using a combination of above-mentioned
positive and negative selection antigens, we performed
advanced flow cytometry analyses and FACS in the adi-
pose SVF in order to identify and simultaneously purify
these MSC precursor subpopulations [23, 24, 39, 101]. Both
CD146+/CD34−/CD45− PCs and CD34+/CD31−/CD45−/
CD146− ACs purified from adipose SVF have been shown to
express MSCmarkers in vivo and in culture [23, 24, 101]. Fur-
thermore, our quantitative multiparameter studies showed
that only a third of adipose PCs (CD146+/CD34−/CD31−/
Lineage−/CD45−) natively coexpress the MSC markers
CD73, CD90, and CD105, which reveals the cellular het-
erogeneity of the pericyte compartment [101]. In contrast,
both CD146+ (putative PC-AC intermediates) and CD146−
(ACs) subsets of CD34+/CD31−/Lineage−/CD45− SVF cells
homogenously co-express MSC markers [101]. On the other
hand, among these MSC-like perivascular cells, two sub-
populations in the adipose SVF can be discerned on the
basis of CD34 expression and further distinguished by their
proliferation pattern: a low proliferative CD34− subset and
a high proliferative CD34+ subset. While CD34− is a typical
phenotype of multipotent mesenchymogenic PCs in adipose
and most other tissues [23], the CD34+ phenotype may
represent transit-amplifying intermediates between stem-like
adipose PCs and highly prevalent ACs in vivo but require
prudent interpretations in culture due to its instability.
5. Adhesion and Migration of Perivascular
MSC Precursors
In view of future stem cell-based approaches and therapies,
it is crucial to identify predictive parameters that allow
the researchers and clinicians to foresee the in vivo action
of stem/progenitor cells. Since cell adhesion and migration
capacities are tightly correlated with in vivo cell trafficking
and homing, these parameters represent potential predictors
for the clinical outcome of stem cell-treated patients and
require further investigation [108–110]. Herein we discuss
recent progresses in the understanding of perivascular MSC
precursors in regard to cell adhesion,migration, and response
to hypoxia.
5.1. Cell Adhesion. Anatomically, PCs closely surround ECs
populating the vascular intima with specific adhesion and
migration properties that allow them to regulate the blood
vessel stability/integrity as well as the proliferation and
motility of adjacent ECs [51]. Up to 1000 contacts can be
secured by peg-sockets to a juxtaposing EC via cytoplas-
mic fingers inserted into endothelial invaginations [111].
Pericytic elongated terminal arms include adhesion plaques
that strongly embed into the basement membrane and EC
body to secure their location [111]. Different molecules
and pathways have been involved in mural cell motility
and adhesion. Notably, ephB/ephrin-B interactions mediate
human MSC/PC adhesion, migration, and differentiation
[112, 113]. The eph/ephrin family of tyrosine kinase receptors
has been identified as an important factor contributing to
bone homeostasis and regulating MSC adhesion. Inhibition
of ephrin-B signaling prevents MSC attachment and spread-
ing by activation of Src-, PI3 Kinase-, and JNK-dependent
signaling pathways [112]. Ephrin-B2-deficient mural cells
displaymajor defects in spreading, focal-adhesion formation,
and polarizedmigration as well as exhibiting increasedmotil-
ity [113]. Our group investigated adhesion molecules and
proteins involved in PCmigratory capacity.We demonstrated
that CD146+/NG2+/PDGFR𝛽+/CD144− PCs exhibitedmore
robust adherence to extracellular matrix substrates (e.g., col-
lagen type-I, gelatin, and fibronectin) and greater migratory
capacity than the CD146− population. Enhanced adherence
and migratory capacities may result from high expression
levels of alpha and beta subunits of integrin and matrix
metalloproteinase (MMP)-2, respectively [70]. On the other
hand, PCs express intercellular adhesion molecule 1 (ICAM-
1) and upregulate its expression in response to tumor necro-
sis factor (TNF) and pattern-recognition receptor (PRR)
ligands. ICAM-1 also regulates interactions of neutrophils
and monocytes with PCs in vitro [114]. Moreover, it has
been suggested that arteriolar and capillary PCs can detect
inflammatory stimuli and increase their adhesive interactions
with innate leukocytes, implicating their role in the regulation
of inflammatory responses [114, 115].
5.2. Cell Migration. PC recruitment and migration occur
frequently in response to pathophysiological events such as
wound healing, inflammation, or angiogenesis. During vas-
cular development, ECs release PDGF-BB to recruit PCs and
stabilize the newly formed blood vessels [116, 117]. Increase
of PC density by activation of PDGF-BB/ PDGFR𝛽 signaling
pathways has also been detected during wound healing and
tumor vascular remodeling [56, 111, 118]. Inversely, disruption
of PDGF-BB/PDGFR𝛽 pathways may occur during patho-
logic conditions (e.g., diabetic retinopathy), resulting in PC
apoptosis and augmented permeability of the vascular wall
[111, 119]. Upon inflammatory events, PCs control the pattern
and efficiency of leukocyte interstitial migration in vivo [114,
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120]. A recent study highlighted the constitutive expres-
sion of chemoattractants by NG2+ PCs: CSC-chemokine
ligand-1 (CXCL1) and -8 (CXCL8), macrophage migration
inhibitory factor (MIF), CC-chemokine ligand 2 (CCL2), and
interleukin-6 (IL-6). PCs further upregulated the expression
of these chemo-attractants following stimulation by PRR
ligands [114, 115]. Therefore, PCs not only chemotactically
migrate to the site of angiogenesis, injury, or inflammation
but also actively recruit other proinflammatory participants,
includingmyeloid leukocytes, neutrophils, andmacrophages.
Using an in vitromodel of tissue damage, some of us pre-
viously mimicked the ability of HUCPCs to migrate towards
the injury site in vivo and predicted their capacity to secrete
cytokines and trophic factors [71]. Envisioning a possible
clinical application of stem cells in the context of extremely
immature newborns with an acute lung injury, where alveolar
type II cells crucial for producing surfactant and regulating
alveolar fluid levels and host defense are damaged, HUC
can be readily considered as a convenient source of stem
cells. Consequently, a coculture model of pulmonary tissue
damage was set up, where an alveolar type II cell line was
damaged with bleomycin, an anticancer drug with known
pulmonary toxicity [71]. Dye-labeled HUCPCs in coculture
were mobilized and migrated towards the damaged alveolar
type II cells. HUCPCs showed a great ability to secrete
angiogenic/antiapoptotic cytokines and trophic factors com-
pared to the control, in particular high level of keratinocyte
growth factor (KGF) [71]. KGF appears to play a crucial role
mediating tissue improvement in a range of experimental
lung injuries, presumably due to its versatile effects including
cellular repair, cytoprotection, and alveolar fluid clearance
modulation and immunomodulation [121, 122]. Similarly,
skeletal muscle-derived PCs secrete high levels (superior to
those of BM-MSCs) of KGF and vascular endothelial growth
factor (VEGF) as well as heparin binding-epidermal growth
factor (HB-EGF) and basic-fibroblast growth factor (bFGF),
which are all considered playing critical roles during wound
healing [123, 124].
The abundance of mesenchymogenic progenitors in the
SVF of adipose tissue (5,000CFU-F per gram) [125] provides
a great advantage for the development of clinical applications
without any in vitro expansion requirements [126, 127]. ASC-
based therapeutic strategies have been proposed for either
regenerative or targeted therapies and often rely on native
tropism of ASCs for wound healing, inflammation, or cancer.
Although investigations of cell adhesion and migration in
purified ACs are currently ongoing, much can be learned
from the unfractionated ASCs which have been shown to
home to sites of injury and promote tissue repair following
systemic injections in animalmodels ofmyocardial infarction
[128, 129], liver injury [130, 131], olfactory dysfunction [132],
hypoxia-ischemia induced brain damage [133], allergic rhini-
tis [134], inflammatory neuropathy [135], sciatic crush [136],
cranial injury [137], and muscular dystrophy [138, 139]. The
migratory activity of early-passage ASCs can be modulated
by a set of chemokines and growth factors, including PDGF-
AB, TGF-𝛽1, and TNF𝛼 [140]. These soluble factors can
stimulate ASCs via activation of an array of migration-
associated receptors such as C-C chemokine receptor types
1 and 7 (CCR1, CCR7), C-X-C chemokine receptor types 4,
5, and 6 (CXCR4, CXCR5, CXCR6), EGF receptor, fibroblast
growth factor receptor 1, TGF-𝛽 receptor 2, TNF receptor
superfamily member 1A, and PDGF receptors 𝛼 and 𝛽 [140–
142].
ASCs have been proposed to affect various neighboring
cells within the subcutaneous tissue via paracrine signals
during active remodeling processes such as wound healing
[143–145]. In a recent study, ASC-conditioned medium pro-
moted in vitro migration of vascular ECs, fibroblasts, and
keratinocytes [146]. These data support the impact of ASCs
on the proliferation and recruitment of these distinct cell
subsets during wound healing via secretion of high levels of
promigratory cytokines, including angiopoietin-like-1, EGF,
FGF, HGF, TGF𝛽, SDF-1, and VEGF [145–149].
Similarly to BM-MSCs [150, 151], ASCs have been asso-
ciated with enhanced migratory activities during tumorige-
nesis. ASC tropism towards various tumors such as glioma
[152, 153], colon cancer [154], and prostate cancer [155] has
been exploited to develop targeted therapies. On the other
hand, ASCs can modulate the migration of cancer cells,
promoting metastasis of breast cancer cells [156, 157] via
CCR5/CCL5 signaling in animal models despite the inhibi-
tion of breast cancer metastasis in a different model [158]. An
antimetastatic result was also observed with pancreas cancer
cells [159].
5.3. Cellular Response to Hypoxia. Hypoxia has been shown
to promote proliferation and migration of both PCs and
MSCs [160, 161]. A recent study highlighted the involvement
of the ERK signaling pathway during the modulation of
mitogenic and chemotactic responses of human muscle PCs
to a low oxygen concentration (6% O
2
). This activation of
ERK signaling and associated integrins occurred without any
detectable alteration on the cell phenotypes or differentiation
potentials [160, 162]. A number of growth factors, including
PDGF, EGF, and FGF, can activate the Ras-Raf-MEK1/2-ERK
signaling axis [163], which controls the adhesion dynamics
and cell migratory properties via formation of protrusions
within cellmembrane and enhancement of the focal adhesion
turnover [164]. Culture of MSCs in hypoxic conditions also
resulted in higher survival and migration in a hind-limb
ischemia model, presumably through Akt signaling [165].
The activation of the Akt pathway has been linked to the
cell migratory ability and can be mediated by hepatocyte
growth factor (HGF). MSCs under hypoxia exhibited higher
expression of cMet, a critical HGF receptor [165, 166], and
two receptors of the chemokine stromal-derived factor-1
(SDF-1), CXCR4 and CXCR7, whose expression can also be
mediated by hypoxia via the hypoxia-inducible factor-1 alpha
(HIF-1𝛼) and Akt phosphorylation [167]. Additionally, even
under a 2.5% O
2
hypoxia, the paracrine function of PCs
remained highly active when compared to 21% O
2
normoxic
culture, with increased expression of VEGF-A, PDGF-B,
and TGF𝛽1 and decreased expression of angiopoietin-1,
bFGF, EGF, HGF, and MCP-1, and similar levels of leukemia
inhibitory factor (LIF), cyclooxygenase-2 (COX-2/PTGS-2,
prostaglandin endoperoxide synthase-2), heme oxygenase-1
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(HMOX-1), IL-6, HIF-1𝛼, and MMP-2 [168]. Understanding
cellular responses of perivascular MSC precursors andMSCs
to hypoxia would help researchers and clinicians to develop
better approaches to improve the efficacy of MSC-based cell
therapy, including genetic modification, cellular precondi-
tioning, and pharmacological adjunct therapy [9].
6. Migratory and Homing Characteristics of
Perivascular MSC Precursors during Tissue
Repair/Regeneration
Perivascular MSC precursors have recently been demon-
strated as efficient regenerative/supportive units for tissue
repair and regeneration. In particular, humanmuscle PCs and
saphenous vein-derived ACs exhibited superior angiogenic,
paracrine, and cardioprotective capacities and augmented
functional recovery in murine myocardial infarction and
hind-limb ischemia models when compared to myoblasts
or unfractionated MSCs [65, 168, 169]. Additionally, muscle
and placental PCs were shown to repair/regenerate injured
and dystrophic muscles in animal disease models as well
as contribute to the muscle stem cell (satellite cell) pool
[23, 64, 70, 170]. Some of us also showed that HUCPCs
prevented/rescued the oxygen-induced arrest in alveolar
growth and restored lung function and architecture, pri-
marily through their paracrine function [171]. Interestingly,
CD146+ PCs extracted from adipose tissue were shown to
support the long-term persistence of human hematopoietic
stem/progenitor cells in coculture [172]. Moreover, purified
human PCs and ACs exhibited bone formation or healing
when implanted into animal models of ectopic bone for-
mation or critical-sized calvarial bone injury, respectively
[88, 89, 173]. In this section, wewill discuss the current under-
standing of the cell engraftment, migration, and homing of
transplanted perivascular MSC precursors during some of
these regenerative events.
6.1. Cardiac Repair. When intramyocardially transplanted
into a mouse model of acute myocardial infarction (AMI),
purified human muscle PCs contributed to cardiac func-
tional and anatomic recovery after infarction, presumably
through multiple cardioprotective and regenerative mecha-
nisms: reversal of ventricular remodeling, reduction of car-
diac fibrosis, diminution of chronic inflammation, promotion
of host angiogenesis, and small-scalemyocardial regenerative
events [168]. The engraftment ratio of intramyocardially
injected GFP-labeled PCs was approximately 9% at the first
week, decreasing to roughly 3% at 8 weeks after infarction.
Above all, a fraction of donor PCs was identified in perivas-
cular positions, juxtaposing host CD31+ ECs (Figure 2). In
contrast to the engraftment ratio, the vessel-homing ratio of
transplanted PCs slightly increased over time, implicating the
potential benefit of niche-homing for long-term donor cell
survival. Moreover, cellular interactions between donor PCs
and host ECswere demonstrated by the expression of human-
specific ephrin type-B receptor 2 (EphB2) in some GFP+
PCs adjacent to ECs as well as the formation of connexin
43 gap junctions with ECs [168]. Additionally, immune cells
Anti-GFP mCD31
Figure 2: Human pericytes home to perivascular locations. Confo-
cal microscopy showed that GFP+ human pericytes (red), identified
by anti-GFP immunostaining, can be located at the interstitial space
where host CD31+ capillaries (green) reside (main, scale bar =
50 𝜇m). Some GFP+ donor cells (inset, red arrows) are in close
contact with mouse CD31+ endothelial cells (green). Dash line in
the inset picture delineates a putative GFP+ cardiomyocyte (inset,
scale bar = 10𝜇m).
in the ischemic tissue release chemokines such as interleukins
and monocyte chemoattractant protein-1 (MCP-1), which
are involved in the homing of MSCs to the ischemic heart
[174]. Moreover, the paracrine anti-inflammatory function of
human MSCs was also demonstrated by the high expression
of anti-inflammatory protein TSG-6 from MSCs embolized
in lung, which led to decreased inflammatory responses,
reduced infarct size, and improved cardiac function [175].
Similarly, Katare et al. reported that transplantation of
human saphenous vein-derived ACs (hSV-ACs), a putative
PC progenitor population, promoted functional improve-
ment in a mouse model of MI, primarily through angiocrine
activities andneovascularization via both donor and recipient
cells as well as other cardioprotective mechanisms includ-
ing improved myocardial blood flow, attenuated vascular
permeability, and reduction of myocardial remodeling, car-
diomyocyte apoptosis, and interstitial fibrosis [169]. hSV-
ACs produced and released microRNA-132 (miR-132) as a
paracrine agent, which exerts proangiogenic, prosurvival,
and antifibrotic activities and likely plays a key role as an
activator of cardiac healing. While retaining their original
antigenic and perivascular phenotype, homing of hSV-ACs
to perivascular locations was confirmed by Dil-labeled hSV-
ACs juxtaposing isolectin-positive capillary ECs [169].
6.2. Muscle Regeneration. As mentioned previously, we
have demonstrated that intramuscular injection of freshly
sorted or cultured PCs derived from human adipose or
skeletal muscle regenerated human myofibers efficiently in
the mouse dystrophic or injured muscle [23]. In another
study, we showed that intramuscular implantation of dis-
sected human placental villi resulted in crude outgrowth
of human cells in dystrophic mice [70]. Ample amount of
cells of human origin released from placental villi fragments
participated in host muscle regeneration, revealed by the
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detection of human dystrophin-positive (hDys3t) and/or
human spectrin-positive myofibers. Many of these human
myofibers coexpressed human lamin A/C, indicating their
sole human origin and not intermediate products of cell
fusion. Surprisingly, human myofibers were located not
only close to the implantation area (500 𝜇m to 2mm) but
also in far more distant regions (up to 2 cm), suggesting
active migration of outgrown human myogenic precursors
over long distances. Similarly, freshly isolated placental PCs
possessed high migratory activity and actively contributed to
host skeletal muscle regeneration [70].
6.3. Pulmonary Repair. As mentioned previously, PCs iso-
lated fromumbilical cordsmigrated efficiently in vitro toward
alveolar type II cells damaged by bleomycin, with an elevated
secretion of KGF and VEGF [71]. Using a preclinical animal
model of oxygen-arrested lung growth (exposure to 95%
oxygen, i.e., hyperoxia), which mimics bronchopulmonary
dysplasia (BPD), Pierro et al. tested the in vivo therapeutic
potential of HUCPCs [171]. To examine suitable approaches
for future clinical applications, two different administration
strategies, prophylactic or therapeutic, as well as two dif-
ferent therapeutic modalities, direct cell transplantation or
HUCPC-conditioned medium injection, were investigated.
Intratracheal transplantation of HUCPCs prevented/rescued
oxygen-induced arrested alveolar growth and restored nor-
mal alveolar architecture.However, immunofluorescence and
qPCR revealed very few donor cells localized within the lung.
This low cell engraftment suggested that cell replacement
is not the primary mechanism of the observed therapeutic
effects. Indeed similar therapeutic benefits can be achieved by
daily intraperitoneal administration of conditioned medium,
resulting in improved alveolar architecture and lung function.
In both administration strategies, long-term efficacy and
safety were demonstrated till 6 months with an improved
exercise capacity and normal alveolar architecture. No sus-
picious tumor formation was noted by total body CT scans.
In conclusion, the therapeutic potential of HUCPCs for
pulmonary repair can be exploited by either direct cell
therapy or the production of trophic factors, expanding new
clinical perspectives for HUCPCs and other perivascular
MSC precursors.
6.4. Skeletal Regeneration. To investigate their skeletal regen-
erative capacity, human PCs and ACs purified from lipoaspi-
rate SVF have been seeded onto osteoinductive scaffolds and
implanted into animal models of ectopic bone formation or
critical-sized calvarial bone injury, respectively [88, 89, 176].
Significantly greater osteogenesis or bone healing by PCs
and ACs in murine muscle pockets or calvarial defects than
control SVF cells was observed, respectively. Additionally,
the high osteogenic capability of human ACs and PCs can
be further enhanced by Nel-like molecule-1 (NELL-1), an
osteoinductive growth factor that is a direct transcriptional
target of Runx2 [89, 173, 176, 177]. On the other hand, the
role of the SDF-1/CXCR4 pathway in MSCs/PCs recruitment
during the injury response has been established in a murine
model of femoral bone graft, where SDF-1 deficient mice
were unable to recruit MSCs at bone fracture sites and
consequently limited their participation to local bone repair
[178]. The role of the SDF-1/CXCR4 axis in PC recruitment
has also been revealed during tumorigenesis [179]. Overex-
pression of PDGF-BB increased malignant PC growth via
activation of the SDF-1/CXCR4 axis and induced expression
of SDF-1 in ECs. The upregulation of SDF-1 was directly
mediated by inhibition of the Akt/mTOR pathway or HIF-
1𝛼. Accordingly, both donor and host stem cell homing
can be further enhanced by MSCs genetically modified to
overexpress SDF-1 [180].
7. Angiogenic Capacities of
Perivascular MSC Precursors and
Cellular Interactions with ECs
7.1. Pericyte-EC Cellular Interactions: A Perivascular Niche for
MSC Precursors. PCs are ubiquitously present in microvas-
culature where they extend primary cytoplasmic processes
along the abluminal surface of the endothelial tube. They are
enveloped in a basement membrane that is continuous with
the EC basement membrane to which both cells contribute
[181, 182].Themajority of the PC-EC interface is separated by
basement membrane, with the two cell types contacting each
other at discrete points through peg-socket type interactions,
occluding contacts, gap junctions, and adhesion plaques [183,
184]. The intimate anatomical relationship between ECs and
PCs suggests close interactions involving not only direct
contact but also paracrine or juxtacrine signaling. EC-to-
PC ratios in normal tissues vary between 1 : 1 to 10 : 1 and
may be up to 100 : 1 (in skeletal muscle), while PC coverage
of the endothelial abluminal surface ranges between 10%
and 70% [185, 186]. PC density and coverage appear to
correlate with endothelial barrier properties (i.e., brain >
lungs > muscle) [111], EC turnover (large turnover leading
to less coverage) [184], and orthostatic blood pressure (larger
coverage in lower body parts) [185], in keeping with a role of
PCs in regulating capillary barriers, endothelial proliferation,
and capillary diameter [111]. Genetically modified mouse
models have demonstrated that these two vascular cell types
are interdependent: primary defects in one cell type have
obligated consequences for the other. There is growing evi-
dence to suggest that ECs can manipulate the migratory and
angiogenic properties of PCs, while in vitro data highlighting
EC influence on mesenchymal differentiation potential of
PCs points to a possible role of ECs as gatekeepers within the
context of an adult stem cell niche.
7.2. EC Interactions Regulate Pericyte Recruitment and Angio-
genesis. Theformation of new capillaries during angiogenesis
requires a series of well-orchestrated cellular events allowing
ECs and PCs to migrate into the perivascular space. In vessel
sprouting, angiogenic factors (e.g., VEGF) stimulate ECs,
which in turn secrete proteases that degrade basement mem-
brane and allow EC invasion. An endothelial column, guided
by a migrating EC at the very tip, then moves toward a VEGF
gradient [183]. Studies of the corpus luteum indicate that PCs
are also capable of guiding sprouting processes by migrating
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Table 1: The influence of ECs on the multipotency of tissue-specific MSCs.
Niche
Component Model
Stem cell
surrogate Niche surrogate
Lineage
assessed
Effect on
differentiation Context
Proposed
mechanism Investigator
Endothelial cell 3D ASC HUVEC Osteogenesis ↓ Paracrine ↑Wnt Rajashekhar et al. [203]
Endothelial cell 3D ASC HUVEC Osteogenesis ↓ Juxtacrine ↑Wnt Rajashekhar et al. [203]
Endothelial cell 2D BMSC HUVEC Osteogenesis ↑ Paracrine
(Dkk1-Wnt, FGF,
PDGF, BMP,
TGF𝛽, Notch)
Saleh et al. [204]
Endothelial cell 2D BMSC HUVEC Adipogenesis — Paracrine — Saleh et al. [205]
Endothelial cell 2D BMSC HUVEC Osteogenesis ↑ Juxtacrine — Xue et al. [206]
Endothelial cell 2D BMSC HDMEC Osteogenesis ↑ Juxtacrine BMP-2 Kaigler et al. [207]
Endothelial cell 2D BMSC HDMEC osteogenesis — Paracrine — Kaigler et al. [207]
Endothelial cell 2D BMSC HDMEC Osteogenesis ↑ Juxtacrine N-cadherin Li et al. [208]
Endothelial cell 2D BMSC HDMEC Osteogenesis ↑ Paracrine VEGF Grellier et al. [209]
Endothelial cell 2D BMSC HDMEC Osteogenesis ↓ Paracrine Osterix/OSX Meury et al. [210]
Endothelial cell 2D BMSC HUVEC Osteogenesis ↑ Juxtacrine Cx43/gap junctions Villars et al. [211]
Endothelial cell 2D BMSC HUVEC Osteogenesis ↑ Juxtacrine — Villars et al. [212]
Endothelial cell 2D HOP HUVEC Osteogenesis ↑ Juxtacrine — Guillotin et al. [213]
Endothelial cell 2D HOP EPC, HSVEC Osteogenesis ↑ Juxtacrine Cx43/gap junctions Guillotin et al. [213]
HUVEC
(a)
Pericyte
(b)
HUVEC pericyte
(c)
Figure 3: Human pericytes support formation of microvascular structures. (a) HUVECs seeded onto Matrigel-coated wells formed typical
capillary-like structures after 24 hours (scale bar = 1mm). (b) Human muscle pericytes formed morphologically similar network structures
within 6–8 hours (scale bar = 1mm). (c) Cocultured dye-labeled HUVECs (red) and pericytes (green) at 1 : 1 ratio on Matrigel showed
coformation of capillary-like networks within 6–8 hours (scale bars = 500 𝜇m).
ahead of ECs and expressing VEGF [187–189]. Emerging
endothelial tubes then secrete growth factors, partly to
attract PCs that envelop the vessel wall, and promote vessel
maturation. Key pathways implicated in PC-EC signaling
include PDGF/PDGFR𝛽, angiopoietins and Tie receptors,
sphingosine-1-phosphate signaling, TGF-𝛽 signaling, Notch
and Wnt [116, 186, 190, 191]. It is believed that PCs, because
of their vessel-embracing position, are able to transfer angio-
genic signals along the vessel length by contacting numerous
ECs. The recruitment and contribution of PCs to developing
endothelial tubes and angiogenic process can be observed
in vitro through Matrigel culture. Human muscle PCs alone
can form network structures in Matrigel culture that were
morphologically similar to networks formed by ECs but at an
accelerated fashion (Figures 3(a) and 3(b)). Coculture of dye-
labeled PCs and ECs at 1 : 1 ratio in Matrigel showed network
formation by both cell types, facilitated by the presence of PCs
(Figure 3(c)). Blocki et al. further demonstrated that while
the capacity to colocalize and/or coform network structures
with endothelial tubules on Matrigel is not restricted to PCs,
only PCs (CD146+/CD34−) effectively stabilize endothelial
networks and improve endothelial sprout integrity [192].
Nevertheless, it is noteworthy that the EC-to-PC ratio may
play an important role in the formation of vascular networks
and PC functionality in vitro.
7.3. ECs:The Gatekeepers of Pericyte Mesenchymal Activation?
A growing number of studies demonstrate that tissue resi-
dent stem cells reside in vascular niches, including neural,
hematopoietic, andMSCs [19, 193–195]. Adult stem cell niche
components provide signals that control the balance between
quiescence, self-renewal, and differentiation [194]. A signif-
icant obstacle in identification of the perivascular origin of
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MSCswas the reluctance of PCs to expressmesenchymal phe-
notypes in their native microenvironment [196]. Although
it is feasible that PCs acquire MSC potentials upon exiting
the microvasculature, it is intuitive that MSC features are
expressed by PCs in situ but environmentally downregulated.
Studies using unfractionated SVF have demonstrated poor
and unreliable tissue formation [197] or lower regeneration
efficacy relative to prospectively isolated and purified MSCs
[197], lending further support to a hypothesis that certain
cellular component(s) of SVF have an inhibitory/adverse
effect on differentiating MSCs. As such, the influence of
ECs on the multipotency of tissue-specific MSCs is now
under investigation even though preliminary results to date
have been divergent (Table 1). Osteogenic and adipogenic
differentiation is not seen within the perivasculature of
healthy tissues where the PC-EC relationship is undisturbed.
However, disturbed PC-EC interactions have been observed
in conditions associated with pathological mineralization
and adipogenesis, for example, heterotopic ossification and
atherosclerosis [198, 199]. In addition, the ECM proteins,
also present within a perivascular niche, have been shown
to modify growth and differentiation of MSCs, with collagen
type I-, fibronectin-, and vitronectin-treated plates enhancing
mineralization in vitro [200].The secretome and proteome of
human MSCs have now been extensively documented [201]
with studies identifying numerous transcription factors and
multiple extracellular and intracellular signaling pathways
that regulate adipogenesis and osteogenesis. Interestingly,
inducers of differentiation along one lineage often inhibit
differentiation along another. For example, the transcription
factor PPAR𝛾 is a prime inducer of adipogenesis that inhibits
osteogenesis, highlighting the mutual exclusivity of these
lineages [202]. It is therefore likely that signalingmechanisms
responsible for the mesenchymal fate of PCs will be multifac-
torial and distinct for different lineages.
8. Conclusion
In this review, we described the identification and character-
ization of perivascular MSC precursors with regard to their
adhesion, migration, engraftment/homing, and intercellular
cross-talk in culture and in experimental animal models.
Although PCs and ACs both exhibit multilineage mesenchy-
mogenic capacities and are derived from adjacent perivas-
cular structural layers, further investigations are required to
clarify their developmental relationship as well as the involve-
ment of an ontogenic intermediate. Through the under-
standing of their unique cellular kinetics and regenerative
potential, we will be able to define the pathophysiological role
and therapeutic value of the individual blood-vessel-derived
MSC precursor population under a particular pathological
circumstance. Ultimately, through the purification and/or
recombination of these distinct subsets of MSC precursors, it
is feasible to further enhance stem cell therapy by eliminating
cells with none or limited regenerative potentials in a specific
disorder, creating a customized therapeutic modality for the
personalized medicine.
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